Details

Analiza predlogov uporabnikov za izboljšanje celovite programske rešitve : diplomsko delo
ID Trkman, Andreja (Author), ID Leben, Anamarija (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (602,89 KB)
MD5: 7339F8EAF6F2F530977FDB2298015FF0
PID: 20.500.12556/rul/37f7ae2e-1c55-4fa6-b807-d32e62250393

Language:Slovenian
Keywords:celovita programska rešitev, procesna usmeritev, poslovni procesi, informacijski sistem, diplomske naloge
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[A. Trkman]
Year:2016
Number of pages:XI, 31 str.
PID:20.500.12556/RUL-90151 This link opens in a new window
UDC:659.2:004:005.81(043.2)
COBISS.SI-ID:4950446 This link opens in a new window
Publication date in RUL:29.03.2017
Views:2017
Downloads:377
Metadata:XML DC-XML DC-RDF
:
TRKMAN, Andreja, 2016, Analiza predlogov uporabnikov za izboljšanje celovite programske rešitve : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : A. Trkman. [Accessed 30 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=90151
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Vpliv izražanja receptorja za inzulinu podoben rastni dejavnik 1 (IGF1R) na preživetje pri razsejanem nedrobnoceličnem raku pljuč
  2. Metastatic EMT phenotype is governed by microRNA-200-mediated competing endogenous RNA networks
  3. Vloga cisteinskih katepsinov B in X in njunih inhibitorjev pri epitelno-mezenhimskem prehodu tumorskih celic
  4. Izolacija in karakterizacija tumorskih matičnih celic iz celičnih linij raka dojke in ovrednotenje izražanja katepsinov B in X v njih
  5. Določanje prisotnosti krožečih tumorskih celic v periferni krvi bolnikov po RO-resekciji raka debelega črevesa in danke
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back